Guide to the preparation, use and quality assurance of blood components

Similar documents
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey

Database on Blood Safety 2009 in ECO Member States

Duration: 12 months May to April

The testing of Donated Blood and Components at NHSBT

Blood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD

Plasma for fractionation: South African Plasma Requirements

Inspections, Compliance, Enforcement, and Criminal Investigations. Central Texas Regional Blood & Tissue Center 07-Nov-03

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies

The establishment of well-organized, nationally-coordinated blood transfusion services with quality systems in all areas

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

Irish Blood Transfusion Service Seirbhís Fuilaistriúcháin na héireann

QSEAL Recovered Plasma Specification

ROLE AND IMPORTANCE OF QIsIN QM AND HV: FROM MONITORING TO IMPROVEMENT AND SAVING

Jovona Powelson, B.S. MLT (ASCP) Director of Laboratories

Irish Blood Transfusion Service Seirbhís Fuilaistriúcháin na héireann

Il ruolo delle VEQ per la sicurezza trasfusionale

Policy for the use of Cytomegalovirus (CMV) negative blood products

L 256/32 Official Journal of the European Union

Adverse Reactions Associated with Methylene Blue Inactivated Fresh Frozen Plasma (MB FFP)

Guidance for Industry

Blood Transfusion. What is blood transfusion? What are blood banks? When is a blood transfusion needed? Who can donate blood?

Blood Donor Counselling

Source of platelet concentrates FACHBEREICH MEDIZIN

HUNGARIAN NATIONAL BLOOD TRANSFUSION SERVICE. Dr. Klara Baroti-Tóth, PhD IPFA/PEI 19 th International Workshop Budapest, May, 2012.

CTYOMEGALOVIRUS (CMV) - BACKGROUND

Non-reproductive tissues and cells Recommending authority/ association

AccuVert HBV Seroconversion Panel PHM941(M) ( )

Impact of donor epidemiology and screening strategies on the safety of blood and plasma for fractionation

National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands. TransMed conference Bhopal 18 November 2016

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

CERTIFIED MAIL RETURN RECEIPT REQUESTED. Esther Hernandez President United States Blood Bank, Inc NW 95th Avenue Miami, Florida

Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen

Allogeneic donor selection and blood collection. by Mohammed Abu-basha

Impact of multi-dye multiplex technology on testing algorithm

Lookback studies to assess viral risks The French experience

Chapter 17: Transfusion-Transmitted Infections (TTI)

CAUTION: Refer to the Document Library for the most recent version of this document. Cryoprecipitate Transfusion Guideline for Practice.

Blood is serious business

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL

GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS

CYTOMEGALOVIRUS (CMV) IgM ELISA Kit Protocol

15. Procuring, processing and transporting gametes and

Policy for the use of Irradiated blood products

Human Cytomegalovirus IgM ELISA Kit

Haemovigilance in Europe: What do health authorities expect from haemovigilance?

EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY

Playing Detective: going in search of the source of infection. Su Brailsford Consultant in Epidemiology and Health Protection

Structure and duties of Blood service

Transfusion Medicine in Saudi Arabia

Annual SHOT Report 2016 Supplementary Information. Chapter 17: Transfusion-Transmitted Infections (TTI)

Transfusion 2004: Current Practice Standards. Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service

Non-reproductive tissues and cells

Blood Supply and Wastage

French National Experience. EFS Medical Director

Human Cytomegalovirus Virus (CMV) IgG ELISA Kit

TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:

Accreditation in the Philippines

TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview

SOP 17 BLOOD BANK. 3. Overall Responsibility: Blood Bank In-Change/Pathologist.

Armed Services Blood Program

N.J.A.C. 8:8-1 et seq.

Blood Components & Indications for Transfusion. Neda Kalhor

Be ready. The INTERCEPT Blood System for Platelets and Plasma pathogen reduction system

UKGS TRANSFUSION SERVICE PRODUCTS AND AVAILABILITY

DIAGNOSTIC AUTOMATION, INC.

All institutions that transfuse blood components and products should implement national and local policies and written procedures for:

CAUTION: Refer to the Document Library for the most recent version of this policy. Policy for the use of Cytomegalovirus (CMV) negative blood products

BLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine

EC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK

HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS. Joana Bikulčienė Director of National blood center

Version for the Silent Procedure 29 April Agenda item January Hepatitis

Non-reproductive tissues and cells

2014/LSIF/PD/008 Building Blocks and Challenges to Implementing a National Blood Program in Malaysia

2014 report. The collection, testing and use of blood and blood components in Europe. M.P. Janssen 1 and G. Rautmann 2

Study of ChLIA and ELISA for TTI Markers in Blood Donors

PROPOSED TECHNICAL REQUIREMENTS BLOOD AND BLOOD COMPONENTS. File 1 DRAFT FOR CONSULTATION PURPOSES ONLY

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE

Keeping blood transfusions safe:

Recombinant Treatments for Bleeding Disorders. An overview of treatments that are considered to have a low risk of viral transmission

See external label 2 C-8 C 96 tests Chemiluminescence. CMV IgM. Cat # Diluted samples, controls & calibrator 100 µl 30 minutes

The Collection, Testing and Use of Blood and Blood Components in Europe

Private Patients Pricelist

Human tissues and cells annual report 2011

Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening

New Advances in Transfusion EM I LY CO BERLY, M D

to be notified: all parties involved in the graduated plan procedure. Annexes

NAT Screening of Blood Donations in NBC, TRCS

REPUBLIC OF LITHUANIA LAW ON DONATION AND TRANSPLANTATION OF HUMAN TISSUES, CELLS AND ORGANS. 19 November 1996 No I-1626 Vilnius

Blood Product Modifications: Leukofiltration, Irradiation and Washing

Objectives. Methods. Results. Economic

Cryopreserved Human Hepatocytes (Cat # HP-F)

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING October2010. Issue Summary

NHSBT Board. Clinical Governance Report 01 October - 30 November 2016

Probability of false initial and repeat ID-NAT reactive donations. Marion Vermeulen IPFA Rome 2014

A. Anti-HIV-1/2, HIV NAT Lookback: for those identified blood and blood components collected:

NATIONAL MARROW DONOR PROGRAM. Creating Connections. Saving Lives. Fran Rabe

Cataloguing-in-Publication (CIP) data. CIP data are available at

Update on WHO Prequalification of In Vitro Diagnostics

Abstract for Blood Bag Production. This abstract refers to blood bag production considering general and process information

Case 1. FDA, Legal, and EBAA Medical Standards Panel. Case 1. Case 1 6/25/2012. Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies

Transcription:

Contents Foreword...3 Members of the European Committee (Partial Agreement) on Blood Transfusion... 8 Members of the GTS working group... 22 Members of the TS066 working group... 30 Recommendation No. R (95) 15 of the Committee of Ministers...40 The Guide to the preparation, use and quality assurance of blood components, Appendix to Recommendation No. R (95) 15 PRINCIPLES... 45 Chapter 1. Principles of a quality system for blood establishments... 47 1. Introduction... 47 2. General Principles... 47 3. Elements of the quality system... 48 4. Premises... 49 5. Qualification and validation... 50 6. Process validation...54 7. Control of equipment and materials...58 8. Documentation... 64 9. Contract management... 67 10. Non-conformance... 69 11. Self-inspection, audits and improvements...72 12. Quality monitoring and control...72 34

Chapter 2. Principles of donor selection...75 1. Overview...75 2. Donor screening...77 3. Specific considerations for donors of different components... 86 4. Example of a donor screening questionnaire...95 Chapter 3. Principles of blood collection... 97 1. Overview... 97 2. Premises for donor sessions... 97 3. Equipment used at blood donation sessions... 98 4. Pre-donation checks and labelling... 98 5. Venepuncture... 98 6. Apheresis... 101 7. Repository of archive samples... 101 8. Management of adverse reactions in donors...102 9. Donor clinic documentation...105 Chapter 4. Principles of blood component processing storage and distribution...107 1. Overview...107 2. Processing procedures...108 3. Choice of anti-coagulant and bag system...109 4. Centrifugation of blood components...111 5. Component separation... 114 6. Leucocyte depletion... 118 7. Freezing and thawing of plasma... 119 8. Open and closed systems and sterile connection devices...121 9. Irradiation of blood components...121 10. Prevention of CMV transmission... 122 11. Pathogen reduction... 123 12. Purity of components... 125 13. Bacterial safety of blood components... 125 35

14. Storage of blood components...129 15. Transportation of blood components... 134 16. Component information and principles of labelling... 136 Chapter 5. Principles of blood component monographs...139 1. Definition and properties...139 2. Preparation... 140 3. Requirements and quality control... 140 4. Storage and transport... 140 5. Labelling... 141 6. Warnings... 141 Chapter 6. Principles of blood components for foetal, neonatal and infant use...143 1. Overview... 143 2. Components for intra-uterine transfusions...144 3. Components for neonatal exchange transfusion...144 4. Red cells for neonatal and infant small volume transfusion... 145 5. Fresh frozen plasma for neonatal and infant use...146 6. Platelets for neonatal and infant use...146 Chapter 7. Principles of pre-deposit autologous transfusion... 149 1. Overview...149 2. Selection of patients for pre-deposit autologous transfusion and blood collection...151 3. Preparation, storage and distribution of pre-deposit autologous components... 153 Chapter 8. Principles of immuno-haematology... 155 1. Overview...155 2. Blood group serological investigations... 156 3. Validation and quality assurance... 157 Chapter 9. Principles of screening for markers of infection...167 1. Overview (general comments for all mandatory tests)...167 2. Algorithm for infectious marker screening and confirmatory testing...168 36

3. Confirmatory testing...170 4. Nucleic acid screening... 171 5. Additional serological testing... 172 Chapter 10. Principles of haemovigilance... 175 1. Overview... 175 2. Prerequisites for implementation of a haemovigilance network...176 3. Types of adverse reactions and adverse events collected in a haemovigilance network... 179 4. Tracing and recall of potentially infectious donations for HIV, HCV or HBV (look-back)... 183 5. Contracts between blood establishments and hospitals for haemovigilance... 185 6. Reporting of haemovigilance data...186 Chapter 11. Principles of clinical use of blood...189 1. Overview...189 2. Elements for a quality system in clinical transfusion...189 3. Clinical indications of blood components...192 4. The request form...201 5. Issuing blood components... 202 6. Administration of blood components... 202 7. Monitoring... 204 8. Transfusion complications... 205 9. Hospital transfusion committees...206 STANDARDS...209 Chapter 1. Standards for a quality system for blood establishments and hospital blood banks... 211 1. Introduction and general principles...211 2. Elements of the quality system...214 Chapter 2. Standards for selection of donors...225 1. Overview...225 2. Information to be provided to the donor...225 37

3. Medical assessment of the donor...227 4. Donor deferral... 229 5. Specific standards for donors of different types of components... 235 6. Post-donation information...241 Chapter 3. Standards for collection of blood and blood components...241 1. Premises for donor sessions...241 2. Procedures and equipment used at blood donation sessions...241 3. Pre-donation checks... 242 4. Labelling... 242 5. Venepucture, bleeding and mixing...243 6. Handling of filled containers and samples...245 7. Special requirement for apheresis...245 8. Repository of archive samples... 246 Chapter 4. Standards for blood component processing, storage and distribution...247 1. Processing... 247 2. Component labelling and information... 248 3. Release of blood components... 249 4. Storage and distribution... 251 5. Irradiation of blood components...252 6. Leucocyte depletion...253 7. Bacterial safety...253 Chapter 5. Component monographs...255 Part A. Whole blood components...257 Part B. Red cell components...265 Part C. Platelet components... 299 Part D. Plasma components... 351 Part E. White cell components... 369 Chapter 6. Standards for blood components for intra-uterine, neonatal and infant use...375 Part A. Components for intra-uterine transfusions...377 38

Part B. Components for neonatal exchange transfusion...383 Part C. Components (small volume) for neonatal and infant transfusion...391 Chapter 7. Standards for autologous pre-deposit transfusion...395 1. Overview...395 2. Selection of patients for PAT and blood collection... 396 3. Preparation, storage and distribution of pre-deposit autologous blood components...397 Chapter 8. Standards for immuno-haematology... 399 1. Overview... 399 2. Selection and validation of reagents and methods... 399 3. Quality control...400 4. Blood group testing of blood donations/donors...400 5. Blood group testing of patients...401 Chapter 9. Standards for screening for infectious markers... 405 1. Selection and validation of infectious marker tests... 405 2. Mandatory serological screening tests...406 3. Additional serological screening tests... 407 4. Management of reactive results in serological screening tests... 407 5. Nucleic acid screening (NAT)...409 6. Selective screening of donations...409 Chapter 10. Standards for haemovigilance... 411 1. Overview... 411 2. Pre-requisites for implementation of a haemovigilance network... 411 3. Device defects...412 4. Post-transfusion reported to the blood establishment...412 Appendices...415 List of definitions...496 Abbreviations... 504 Recommendations and resolutions of the Council of Europe in the field of blood transfusion... 507 List of publications... 509 39